|
|
Article: Celgene Corporation Reports Strong Operating, Regulatory and Clinical Results with Record Product Sales.
- Article from:
- PR Newswire
- Article date:
- November 3, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Third Quarter Highlights:
- Total Product Sales for the Third Quarter Reached a Record $113.9 Million, 36% Increase Year-Over-Year
- Commercial Team Finalized Preparations for REVLIMID(R) Launch As First Oral Targeted Therapy For Low To Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality
- FDA Oncologic Drugs Advisory Committee Recommended REVLIMID for Full Approval, by a 10-5 vote, As Oral Targeted Therapy For Low To Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality; PDUFA Date Extended to January 7, 2006
- REVLIMID Marketing Authorization Application (MAA) Accepted by the EMEA to Evaluate ...